PO.MCB04.01 · 分子与细胞生物学

缺氧筛选出早期PI3K通路改变并驱动HPV阳性口咽癌的克隆复杂性

Hypoxia selects for early PI3K pathway alterations and drives clonal complexity in HPV-positive oropharyngeal cancer

海报缩略图:缺氧筛选出早期PI3K通路改变并驱动HPV阳性口咽癌的克隆复杂性
编号 7291 展板 3 时间 4/22 09:00–12:00 区域 Section 22 主讲 Bill Diplas, MD;PhD
分会场 Hypoxic and Proteotoxic Stress Response
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Bill Diplas, Xin Pei, Yingjie Zhu, Shu Yazaki, Luc G.T. Morris, Richard J. Wong, Sean M. McBride, Heiko Schoder, Yao Yu, Alan L. Ho, Eric Sherman, Nora Katabi, Nancy Lee, Nadeem Riaz

Memorial Sloan Kettering Cancer Center, New York, NY

摘要 Abstract

中文摘要
目的:肿瘤缺氧驱动头颈癌的治疗耐药,但其分子决定因素仍不明确。我们此前证实,表现出缺氧的HPV相关口咽癌(OPC)更具侵袭性,需要强化治疗。在此,我们研究了肿瘤缺氧的遗传驱动因素及其对肿瘤演化的影响。 方法:我们分析了来自一项前瞻性缺氧导向剂量降级试验(NCT03323463)的152例早期HPV相关OPC患者。全面的基因组分析包括WES(n=122)和RNA-seq(n=91)。肿瘤缺氧采用18F-FMISO PET评估,使用标准化的混合方法,结合对四种图像特征的定性评估和定量的肿瘤-背景比值(TBR>1.3视为缺氧)。克隆结构使用PhylogicNDT重建。我们在来自TCGA和JAVELIN-HN的两个独立HPV相关口咽癌队列中验证了缺氧的分子相关性。验证队列中的缺氧采用三种已确立的基于mRNA的缺氧特征(Buffa、Winter、Toustrup)确定。 结果:由FMISO PET确定的缺氧在基线时存在于72%的肿瘤中,且与已确立的基于RNA的缺氧特征相关。突变谱分析显示,缺氧肿瘤富集PI3K通路改变,最显著的是PIK3CA突变(OR=5.45,校正p=0.05)。关键的是,这种关联仅限于克隆性PIK3CA突变——亚克隆突变未显示与缺氧的关联,提示在缺氧条件下的早期选择。这种缺氧-PI3K关系在独立的HPV-OPC队列(TCGA、JAVELIN-HN)中,使用基于表达的缺氧特征得到验证(Winter、Buffa和Toustrup缺氧特征的校正p<0.05)。最后,克隆图谱进一步揭示,缺氧肿瘤表现出显著更大的克隆复杂性(p<0.05;Shannon多样性)。对41例肿瘤子集的多区域测序证实了广泛的空间异质性,与缺氧肿瘤强相关。 结论:我们的研究结果表明,缺氧驱动PI3K通路改变的早期选择并促进克隆复杂性,展示了微环境如何引导HPV相关OPC的肿瘤演化。
查看英文原文 English abstract
Purpose: Tumor hypoxia drives treatment resistance in head and neck cancer, yet its molecular determinants remain unclear. We previously demonstrated that HPV-related oropharyngeal cancer (OPC) exhibiting hypoxia is more aggressive necessitating escalated treatment. Here, we investigated the genetic drivers of tumor hypoxia and their impact on tumor evolution. Methods: We analyzed 152 patients with early-stage HPV-related OPC from a prospective hypoxia-directed dose de-escalation trial (NCT03323463). Comprehensive genomic profiling included WES (n=122) and RNA-seq (n=91). Tumor hypoxia was assessed using 18F-FMISO PET with a standardized hybrid method incorporating qualitative assessment of four image characteristics and quantitative tumor-to-background ratios (TBR >1.3 considered hypoxic). Clonal architecture was reconstructed using PhylogicNDT. We validated molecular correlates of hypoxia in two independent cohorts of HPV-related oropharyngeal cancer from the TCGA and JAVELIN-HN. Hypoxia in validation cohorts was determined using three established mRNA-based hypoxia signatures (Buffa, Winter, Toustrup). Results: Hypoxia as determined by FMISO PET was present in 72% of tumors at baseline, and correlated with well-established RNA-based signatures of hypoxia. Mutational profiling showed that hypoxic tumors were enriched for PI3K pathway alterations, most notably PIK3CA mutations (OR=5.45, adjusted p=0.05). Critically, this association was restricted to clonal PIK3CA mutations-subclonal mutations showed no hypoxia association, suggesting early selection under hypoxic conditions. This hypoxia-PI3K relationship was validated in independent cohorts of HPV-OPC (TCGA, JAVELIN-HN) using expression-based signatures of hypoxia (adjusted p<0.05 for Winter, Buffa and Toustrup hypoxia signatures). Lastly, clonal mapping further revealed that hypoxic tumors exhibited significantly greater clonal complexity (p < 0.05; Shannon diversity). Multi-region sequencing in a subset of 41 tumors confirmed extensive spatial heterogeneity, strongly linked to hypoxic tumors. Conclusions: Our findings show that hypoxia drives early selection for PI3K pathway alterations and promotes clonal complexity, demonstrating how the microenvironment directs tumor evolution in HPV-related OPC.
利益披露 Disclosure
B. Diplas, None.. X. Pei, None.. Y. Zhu, None.. S. Yazaki, None. L. G. Morris, PGDX Patent. R. J. Wong, None. S. M. McBride, Janssen Independent Contractor. AstraZeneca Independent Contractor, ). Genentech ). Y. Yu, None. A. L. Ho, Rgenta Stock. Eisai Independent Contractor. Merck Independent Contractor. Ayala Pharmaceuticals Independent Contractor. Prelude Therapeutics Independent Contractor. Kura Oncology Independent Contractor. AffyImmune Therapeutics Independent Contractor. Exelixis Independent Contractor. Cellestia Biotech Independent Contractor. InxMed Independent Contractor. Remix Therapeutics Independent Contractor. Elevar Therapeutics Independent Contractor. Coherus Biosciences Independent Contractor. N. Katabi, None. N. Lee, Merck Independent Contractor. Mirati Therapeutics Independent Contractor. Elsie Pharmaceuticals Independent Contractor. Galera Therapeutics Independent Contractor. Nanobiotix Independent Contractor. Regeneron Independent Contractor. Varian Medical Systems Travel. N. Riaz, Mirati Therapeutics Independent Contractor. Repare Therapeutics Independent Contractor. Illumina Independent Contractor. Bristol Myers Squibb ). Pfizer ). Repare Therapeutics ). Paige.AI ). Varian Medical Systems Travel.

← 返回 AACR 2026 检索